Leah S Richmond-Rakerd1,2, Jacqueline M Otto1,2, Wendy S Slutske1,2, Cindy L Ehlers3, Kirk C Wilhelmsen4, Ian R Gizer1,2. 1. Department of Psychological Sciences, University of Missouri, Columbia, MO. 2. Alcoholism Research Center at Washington University School of Medicine, St. Louis, MO. 3. Department of Molecular and Cellular Neurosciences (CLE), The Scripps Research Institute, La Jolla, CA. 4. Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract
INTRODUCTION: Tobacco use is associated with variation at the 15q25 gene cluster and the cytochrome P450 (CYP) genes CYP2A6 and CYP2B6. Despite the variety of outcomes associated with these genes, few studies have adopted a data-driven approach to defining tobacco use phenotypes for genetic association analyses. We used factor analysis to generate a tobacco use measure, explored its incremental validity over a simple indicator of tobacco involvement: cigarettes per day (CPD), and tested both phenotypes in a genetic association study. METHODS: Data were from the University of California, San Francisco Family Alcoholism Study (n = 1942) and a Native American sample (n = 255). Factor analyses employed a broad array of tobacco use variables to establish the candidate phenotype. Subsequently, we conducted tests for association with variants in the nicotinic acetylcholine receptor and CYP genes. We explored associations with CPD and our measure. We then examined whether the variants most strongly associated with our measure remained associated after controlling for CPD. RESULTS: Analyses identified one factor that captured tobacco-related problems. Variants at 15q25 were significantly associated with CPD after multiple testing correction (rs938682: p = .00002, rs1051730: p = .0003, rs16969968: p = .0003). No significant associations were obtained with the tobacco use phenotype; however, suggestive associations were observed for variants in CYP2B6 near CYP2A6 (rs45482602: ps = .0082, .0075) and CYP4Z2P (rs10749865: ps = .0098, .0079). CONCLUSIONS: CPD captures variation at 15q25. Although strong conclusions cannot be drawn, these finding suggest measuring additional dimensions of problems may detect genetic variation not accounted for by smoking quantity. Replication in independent samples will help further refine phenotype definition efforts. IMPLICATIONS: Different facets of tobacco-related problems may index unique genetic risk. CPD, a simple measure of tobacco consumption, is associated with variants at the 15q25 gene cluster. Additional dimensions of tobacco problems may help to capture variation at 19q13. Results demonstrate the utility of adopting a data-driven approach to defining phenotypes for genetic association studies of tobacco involvement and provide results that can inform replication efforts.
INTRODUCTION: Tobacco use is associated with variation at the 15q25 gene cluster and the cytochrome P450 (CYP) genes CYP2A6 and CYP2B6. Despite the variety of outcomes associated with these genes, few studies have adopted a data-driven approach to defining tobacco use phenotypes for genetic association analyses. We used factor analysis to generate a tobacco use measure, explored its incremental validity over a simple indicator of tobacco involvement: cigarettes per day (CPD), and tested both phenotypes in a genetic association study. METHODS: Data were from the University of California, San Francisco Family Alcoholism Study (n = 1942) and a Native American sample (n = 255). Factor analyses employed a broad array of tobacco use variables to establish the candidate phenotype. Subsequently, we conducted tests for association with variants in the nicotinic acetylcholine receptor and CYP genes. We explored associations with CPD and our measure. We then examined whether the variants most strongly associated with our measure remained associated after controlling for CPD. RESULTS: Analyses identified one factor that captured tobacco-related problems. Variants at 15q25 were significantly associated with CPD after multiple testing correction (rs938682: p = .00002, rs1051730: p = .0003, rs16969968: p = .0003). No significant associations were obtained with the tobacco use phenotype; however, suggestive associations were observed for variants in CYP2B6 near CYP2A6 (rs45482602: ps = .0082, .0075) and CYP4Z2P (rs10749865: ps = .0098, .0079). CONCLUSIONS: CPD captures variation at 15q25. Although strong conclusions cannot be drawn, these finding suggest measuring additional dimensions of problems may detect genetic variation not accounted for by smoking quantity. Replication in independent samples will help further refine phenotype definition efforts. IMPLICATIONS: Different facets of tobacco-related problems may index unique genetic risk. CPD, a simple measure of tobacco consumption, is associated with variants at the 15q25 gene cluster. Additional dimensions of tobacco problems may help to capture variation at 19q13. Results demonstrate the utility of adopting a data-driven approach to defining phenotypes for genetic association studies of tobacco involvement and provide results that can inform replication efforts.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Marissa A Ehringer; Hilary V Clegg; Allan C Collins; Robin P Corley; Thomas Crowley; John K Hewitt; Christian J Hopfer; Kenneth Krauter; Jeffrey Lessem; Soo Hyun Rhee; Isabel Schlaepfer; Andrew Smolen; Michael C Stallings; Susan E Young; Joanna S Zeiger Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-07-05 Impact factor: 3.568
Authors: Li-Shiun Chen; Nancy L Saccone; Robert C Culverhouse; Paige M Bracci; Chien-Hsiun Chen; Nicole Dueker; Younghun Han; Hongyan Huang; Guangfu Jin; Takashi Kohno; Jennie Z Ma; Thomas R Przybeck; Alan R Sanders; Jennifer A Smith; Yun Ju Sung; Angie S Wenzlaff; Chen Wu; Dankyu Yoon; Ying-Ting Chen; Yu-Ching Cheng; Yoon Shin Cho; Sean P David; Jubao Duan; Charles B Eaton; Helena Furberg; Alison M Goate; Dongfeng Gu; Helen M Hansen; Sarah Hartz; Zhibin Hu; Young Jin Kim; Steven J Kittner; Douglas F Levinson; Thomas H Mosley; Thomas J Payne; D C Rao; John P Rice; Treva K Rice; Tae-Hwi Schwantes-An; Sanjay S Shete; Jianxin Shi; Margaret R Spitz; Yan V Sun; Fuu-Jen Tsai; Jen C Wang; Margaret R Wrensch; Hong Xian; Pablo V Gejman; Jiang He; Steven C Hunt; Sharon L Kardia; Ming D Li; Dongxin Lin; Braxton D Mitchell; Taesung Park; Ann G Schwartz; Hongbing Shen; John K Wiencke; Jer-Yuarn Wu; Jun Yokota; Christopher I Amos; Laura J Bierut Journal: Genet Epidemiol Date: 2012-05 Impact factor: 2.135
Authors: Nancy L Saccone; Robert C Culverhouse; Tae-Hwi Schwantes-An; Dale S Cannon; Xiangning Chen; Sven Cichon; Ina Giegling; Shizhong Han; Younghun Han; Kaisu Keskitalo-Vuokko; Xiangyang Kong; Maria Teresa Landi; Jennie Z Ma; Susan E Short; Sarah H Stephens; Victoria L Stevens; Lingwei Sun; Yufei Wang; Angela S Wenzlaff; Steven H Aggen; Naomi Breslau; Peter Broderick; Nilanjan Chatterjee; Jingchun Chen; Andrew C Heath; Markku Heliövaara; Nicole R Hoft; David J Hunter; Majken K Jensen; Nicholas G Martin; Grant W Montgomery; Tianhua Niu; Thomas J Payne; Leena Peltonen; Michele L Pergadia; John P Rice; Richard Sherva; Margaret R Spitz; Juzhong Sun; Jen C Wang; Robert B Weiss; William Wheeler; Stephanie H Witt; Bao-Zhu Yang; Neil E Caporaso; Marissa A Ehringer; Tim Eisen; Susan M Gapstur; Joel Gelernter; Richard Houlston; Jaakko Kaprio; Kenneth S Kendler; Peter Kraft; Mark F Leppert; Ming D Li; Pamela A F Madden; Markus M Nöthen; Sreekumar Pillai; Marcella Rietschel; Dan Rujescu; Ann Schwartz; Christopher I Amos; Laura J Bierut Journal: PLoS Genet Date: 2010-08-05 Impact factor: 5.917
Authors: Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean Journal: Nature Date: 2012-11-01 Impact factor: 49.962
Authors: S P David; A Hamidovic; G K Chen; A W Bergen; J Wessel; J L Kasberger; W M Brown; S Petruzella; E L Thacker; Y Kim; M A Nalls; G J Tranah; Y J Sung; C B Ambrosone; D Arnett; E V Bandera; D M Becker; L Becker; S I Berndt; L Bernstein; W J Blot; U Broeckel; S G Buxbaum; N Caporaso; G Casey; S J Chanock; S L Deming; W R Diver; C B Eaton; D S Evans; M K Evans; M Fornage; N Franceschini; T B Harris; B E Henderson; D G Hernandez; B Hitsman; J J Hu; S C Hunt; S A Ingles; E M John; R Kittles; S Kolb; L N Kolonel; L Le Marchand; Y Liu; K K Lohman; B McKnight; R C Millikan; A Murphy; C Neslund-Dudas; S Nyante; M Press; B M Psaty; D C Rao; S Redline; J L Rodriguez-Gil; B A Rybicki; L B Signorello; A B Singleton; J Smoller; B Snively; B Spring; J L Stanford; S S Strom; G E Swan; K D Taylor; M J Thun; A F Wilson; J S Witte; Y Yamamura; L R Yanek; K Yu; W Zheng; R G Ziegler; A B Zonderman; E Jorgenson; C A Haiman; H Furberg Journal: Transl Psychiatry Date: 2012-05-22 Impact factor: 6.222